Reported about 1 month ago
Novavax faces significant challenges as the FDA has placed a halt on its combined coronavirus and flu vaccine program following a serious adverse event reported during a trial. This setback comes at a time when the company aimed to capture a share of the lucrative flu shot market, which is increasingly competitive with other players like Moderna advancing in similar vaccine development. The uncertainty surrounding the FDA's investigation and the overall market reception of Novavax's current offerings adds risk for investors considering the biotech's stock.
Source: YAHOO